SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

SEGALA, Daniela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.163
AS - Asia 4.635
EU - Europa 3.899
SA - Sud America 827
AF - Africa 97
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 7
Totale 16.642
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.944
SG - Singapore 2.143
IT - Italia 1.434
CN - Cina 1.146
PL - Polonia 762
BR - Brasile 696
DE - Germania 532
HK - Hong Kong 520
VN - Vietnam 319
GB - Regno Unito 236
FI - Finlandia 178
RU - Federazione Russa 153
ID - Indonesia 134
UA - Ucraina 132
SE - Svezia 123
MX - Messico 102
CA - Canada 93
TR - Turchia 89
IN - India 82
FR - Francia 74
NL - Olanda 73
AR - Argentina 57
AT - Austria 50
BD - Bangladesh 45
ES - Italia 35
ZA - Sudafrica 35
JP - Giappone 30
LT - Lituania 29
BE - Belgio 25
IQ - Iraq 22
EC - Ecuador 16
CO - Colombia 15
KE - Kenya 14
CZ - Repubblica Ceca 13
CL - Cile 12
MA - Marocco 12
IE - Irlanda 11
AE - Emirati Arabi Uniti 10
PY - Paraguay 10
TH - Thailandia 10
AU - Australia 9
CH - Svizzera 9
CM - Camerun 9
EG - Egitto 8
KR - Corea 8
MY - Malesia 8
PE - Perù 8
PK - Pakistan 8
UZ - Uzbekistan 8
VE - Venezuela 8
IL - Israele 6
SA - Arabia Saudita 6
TN - Tunisia 6
DO - Repubblica Dominicana 5
EU - Europa 5
HN - Honduras 5
PH - Filippine 5
AL - Albania 4
BG - Bulgaria 4
DZ - Algeria 4
KZ - Kazakistan 4
NO - Norvegia 4
AZ - Azerbaigian 3
DK - Danimarca 3
GE - Georgia 3
IR - Iran 3
JM - Giamaica 3
NP - Nepal 3
OM - Oman 3
PS - Palestinian Territory 3
RS - Serbia 3
TT - Trinidad e Tobago 3
BY - Bielorussia 2
GT - Guatemala 2
JO - Giordania 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LU - Lussemburgo 2
NZ - Nuova Zelanda 2
PA - Panama 2
SN - Senegal 2
SR - Suriname 2
SY - Repubblica araba siriana 2
UY - Uruguay 2
AP - ???statistics.table.value.countryCode.AP??? 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CV - Capo Verde 1
DM - Dominica 1
GA - Gabon 1
GR - Grecia 1
HU - Ungheria 1
IM - Isola di Man 1
KG - Kirghizistan 1
KI - Kiribati 1
LB - Libano 1
MD - Moldavia 1
Totale 16.627
Salva come PNG Salva come JPEG
Città #
Ashburn 1.141
Singapore 1.122
Warsaw 755
Beijing 614
Fairfield 588
Santa Clara 582
Hong Kong 519
Chandler 348
Woodbridge 309
Houston 248
Munich 248
Wilmington 237
Seattle 230
Cambridge 176
Los Angeles 176
Princeton 154
Dallas 143
Ferrara 137
Jakarta 115
Ho Chi Minh City 112
Ann Arbor 111
Milan 104
Jacksonville 103
New York 98
Helsinki 86
Rome 78
Mexico City 74
Shanghai 70
Dong Ket 69
San Diego 68
London 64
Turku 64
São Paulo 62
Bremen 59
Nuremberg 56
Bologna 54
Hanoi 53
Izmir 47
Brooklyn 46
Washington 43
Chicago 40
Boardman 39
Falls Church 37
Nanjing 37
Frankfurt am Main 34
Stockholm 32
Redwood City 31
Verona 31
Chennai 30
Tokyo 29
Buffalo 28
Atlanta 27
Boston 27
Dearborn 27
Denver 27
Falkenstein 27
Addison 26
Johannesburg 26
Rio de Janeiro 26
Toronto 26
Montreal 25
San Francisco 25
The Dalles 25
Moscow 24
Brussels 23
Orem 22
Phoenix 22
Poplar 22
Santa Maria Di Sala 22
Amsterdam 21
Hefei 20
Manchester 20
Tianjin 20
Vienna 19
Belo Horizonte 18
Naples 17
Mountain View 15
Norwalk 15
San Mateo 15
Charlotte 14
Council Bluffs 14
Padova 14
Ankara 13
Da Nang 12
Nairobi 12
Augusta 11
Brasília 11
Portsmouth 11
Nanchang 10
Porto Alegre 10
Shenyang 10
Birmingham 9
Columbus 9
Curitiba 9
Dhaka 9
Fortaleza 9
Goiânia 9
Lappeenranta 9
Lauterbourg 9
Palermo 9
Totale 10.583
Salva come PNG Salva come JPEG
Nome #
Endocardite da Bartonella henselae? Riscontro di anticorpi anti-fosfolipidi, anti-beta2-glicoproteina e anti-cardiolipina. 668
Daclatasvir + Sofosbuvir +/- Ribavirin in HIV/HCV co-infected patients with advanced liver disease: preliminary data from the Italian Compassionate Use Program 313
INTERVENTO DI FORMAZIONE/INFORMAZIONE CIRCA LE MODALITÀ DI TRASMISSIONE/PREVENZIONE DI MALATTIE SESSUALMENTE TRASMISSIBILI (SDTS) AD UNA POPOLAZIONE DI MIGRANTI RICHIEDENTI ASILO/RIFUGIATI CON OFFERTA ATTIVA DEL TEST HIV. STUDIO PILOTA NELLA PROVINCIA DI FERRARA. DATI PRELIMINARI 237
INDAGINE RETROSPETTIVA DELLE LINFOADENOPATIE INFETTIVE. RUOLO DEI TESTS MOLECOLARI. 204
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 191
Proportion of PLWH not vaccinated for COVID-19 in Italy and predictors 188
INFEZIONI DEL SISTEMA NERVOSO CENTRALE E CHLAMYDIA PNEUMONIAE. RUOLO ETIOPATOGENETICO NELLA SCLEROSI MULTIPLA 183
Investigation of Chlamydia pneumonite and Mycoplasma spp. In clinical specimens from patients with arhritis 173
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: data from the Icona cohort 161
EPATITE CRONICA C E SINDROME DI EHLERS DANLOS (EDS). 154
Expression of toxoplasmic 65 kDa cystic mRNA by RT-PCR in patients with Toxoplasma gondii infection relapses 153
The role of stage-specific oligonucleotide primers in providing effective laboratory support for the molecular diagnosis of reactivated Toxoplasma gondii encephalitis in patients with AIDS 152
Health education and HIV test offer in a population of refugees and asylum seekers: an experience in Ferrara area. 151
Recovery of Enterococcus gallinarum in patients with infected cardiac pacemaker pockets. 149
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 149
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 149
Approccio multidisciplinare per il trattamento delle osteomieliti croniche e delle infezioni di dispositivi ortopedici. Risultati Preliminari 147
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 146
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 144
Entheseal involvement in asymptomatic human immunodeficiency virus infected patients: preliminary results of a clinical and ultrasonographic study 140
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection 139
L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV 139
HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients 136
Factors that influence HCV related liver disease severity in Italian patients in care: data from PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti ViRali) HCV cohort study". 135
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 135
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 134
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 134
Evaluation of HIV Antiretroviral Therapy, Residual Viremia, and Immune Replacement as Possible Factors that Can Affect Systemic Inflammation 132
RISPOSTA VIROLOGICA SOSTENUTA DOPO TRATTAMENTO BREVE CON DI PEGINTERFERON ALFA-2A E RIBAVIRINA IN CORSO DI EPATITE CRONICA DA HCV 131
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 129
Therapeutic immunization with hiv-1 tat reduces immune activation and loss of regulatory t-cells and improves immune function in subjects on HAART 129
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 129
TB meningitis in HIV-positive patients in Europe and Argentina: Clinical dutcome and factors associated with mortality 128
Implicazioni diagnostiche e terapeutiche in un paziente con Infezione da Parvovirus B-19 e sarcoidosi 127
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 125
ISS-NIA ITALIAN COHORT: NEW ANTI-HIV INHIBITORS IN PATIENTS EXPERIENCED TO IP, NRTI, NNRTI 125
Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated HCV-related condition in the real life practice 125
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 124
Incidence and determinants of antiretroviral switching away from TDF-based backbone in the recent years in the Icona Foundation Cohort 124
Disease progression in HIV Late Presenters: The role of HIV clinical indicator diseases prior to HIV diagnosis 123
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 123
Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: A multicentre cohort study Disease epidemiology - Infectious 122
A prospective randomized trial on abacavir/ lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study) 121
Atazanavir/rit(atz/r),unboosted atazanavir (atz) or darunavir/rit(drv/r):metabolic safety and liver fibrosis in hiv/hcv coinfected patients (master cohort) 121
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors 120
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment 119
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 119
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration 118
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort * 116
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 116
Virological response to treatment in patient who start raltegravir in combination with newer agents in current clinical practice 116
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 115
EVALUATION OF THE SWITCH TO A DUAL ART REGIMEN WITH LAMIVUDINE PLUS DOLUTEGRAVIR OR PROTEASE INHIBITORS IN HIV-INFECTED VIROLOGICALLY SUPPRESSED PATIENTS. A REAL LIFE EXPERIENCE 112
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study 112
Procalcitonin Predicts Bacterial Infection, but Not Long-Term Occurrence of Adverse Events in Patients with Acute Coronary Syndrome 111
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing 110
Limited occurence of new grade 3-4 toxicity events with salvage regimens based on raltegravir and /or maraviroc: 96 weeks data from the ISS NIA cohort study 110
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir± ribavirin in HIV/HCV co-infected patients 109
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 109
Broncopolmonite con empieva pleurico da Streptococcus pluranimalium in paziente tossicodipendente: considerazioni clinico-epidemiologiche. 109
Three-years follow up of raltegravir and/or maraviroc-based regimens in patients experienced to PI, NRTI, NNRTI. Update from the ISS-NIA cohort 108
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 108
Multidrug Resistant Bacterial Co-Infections in Critically Ill Patients with COVID-19: A Review after Three Years of Pandemic 107
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 106
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients 106
null 106
Co-Infections in Critically Ill Patients with or without COVID-19: A Comparison of Clinical Microbial Culture Findings 106
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 105
PITER-HCV cohort study as part of the Italian platform for the study of viral hepatitis therapies 105
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: Data from the ICONA foundation study group, years 1997-2013 105
Associations between immune depression and cardiovascular events in HIV infection 104
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 103
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: The D:A:D Study a 102
CD4+ T- cell count and CD4/CD8 ratio trend after HCV eradication in HCV/HIV-coinfected subjects treated with DAAs: an observational retrospective study over a 4 year period. 102
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: Data from the Icona Foundation cohort 101
The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study 99
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 99
Antiretroviral Therapy Partially Restores Phenotypic and Metabolic Immunosenescence Features of T Cells in Hiv Infected Individuals 98
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 97
Predictors of access and response to DAA in a cohort of human immunodeficiency virus/hepatitis C virus co-infected patients in Italy 97
Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study 97
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 95
Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program 95
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D study 95
Antiretroviral Regimens Containing Atazanavir/Ritonavir (ATZ/R) Unboosted Atazanavir (ATZ) or Darunavir/Ritonavir (DRV/R) in HIV/HCV-coinfected Patients: Evaluation of Safety, Effectivness And Impact on Liver Fibrosis (MASTER Cohort) 95
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 94
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 94
Time to undetectable viral load achievement after art start and risk of mortality. 94
COVID-19 in eastern Emilia: an unusual epidemiology in Northern Italy 94
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 93
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 93
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 92
Endocrinological aspects of hypophosphatemia in HIV infection. Pilot study on Vitamin D supplementation: an observational study 92
Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study 90
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 90
GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial 89
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 89
Evolution and reversibility of renal function after switch from TDF to TAF regimens 89
Serious liver events and liver-related deaths in HIV/HCV co-infected patients with diabetes: data from the ICONA Foundation Cohort Study. 89
La applicazione delle Linee Guida Italiane di terapia antiretrovirale nella realtà ambulatoriale: efficacia e tollerabilità della cART di prima linea. 88
Totale 12.774
Salva come PNG Salva come JPEG
Categoria #
all - tutte 100.767
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.025
Totale 102.792
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.422 0 0 0 0 0 303 224 211 124 310 89 161
2021/20221.086 74 96 23 15 57 89 56 65 38 121 53 399
2022/2023988 158 65 66 54 173 92 52 95 117 12 71 33
2023/20241.102 55 100 82 41 115 223 27 74 34 29 37 285
2024/20254.195 101 88 350 163 469 482 155 167 683 550 540 447
2025/20265.133 1.035 396 811 1.120 1.652 119 0 0 0 0 0 0
Totale 17.049